Clinical Trials Logo

Clinical Trial Summary

Thrombocytopenia is an important pathological feature of HFRS(Hemorrhagic Fever With Renal Syndrome, HFRS). However, the cause of thrombocytopenia in HFRS is not yet fully understood. Neutrophils, as the largest number of white blood cells in the human body, can widely participate in the immune process of viral infections. Previous studies have found that the neutrophils of patients with acute myocardial infarction can interact with activated platelets and further mediate platelet phagocytosis.Therefore, this study aims to systematically elucidate the immunological process of neutrophil mediated thrombocytopenia in patients with HFRS by exploring the correlation between platelet activation, neutrophil activation and neutrophil proportion of adherent / phagocytic platelets peripheral blood of HFRS patients, and to analyze its relationship with the course of HFRS disease, which lays a theoretical foundation for further understanding the pathogenesis of HFRS and provides a basis for clinical use.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04834713
Study type Observational
Source First Affiliated Hospital Xi'an Jiaotong University
Contact xiaojiao Li
Phone 0086-17521011271
Email lixiaojiao@xjtufh.edu.cn
Status Recruiting
Phase
Start date October 9, 2020
Completion date February 28, 2024

See also
  Status Clinical Trial Phase
Withdrawn NCT00868946 - Ribavirin for Hemorrhagic Fever With Renal Syndrome in Germany Phase 2
Recruiting NCT04323904 - Hantavirus Registry - HantaReg
Completed NCT02116205 - Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever Phase 2
Completed NCT02455375 - Diagnostic of Puumala Virus Infection in France
Completed NCT01502345 - Study to Evaluate the Safety, Tolerability, and Immunogenicity of Hantaan and Puumala Virus DNA Vaccines Phase 1
Enrolling by invitation NCT00623168 - Ribavirin for Hemorrhagic Fever With Renal Syndrome Phase 2